PDCD1 and neoplasm: The results presented in Figure 6C and 6D show addition of anti-PD-L1 antibodies resulted in augmenting the frequency of CD3 T-cell (comprising CD8 T-cells) infiltration into the tumor site, suggesting that PD-1 blockade affects the persistence and function of tumor-infiltrating lymphocytes in the tumor microenvironment.